Spectral AI
MDAI

$1.05

2.78%

Market Cap: $18.5M

About: Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Employees: 78

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2.81% less ownership

Funds ownership: 18.47% [Q1] → 15.66% (-2.81%) [Q2]

12% less funds holding

Funds holding: 25 [Q1] → 22 (-3) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

30% less capital invested

Capital invested by funds: $6.65M [Q1] → $4.63M (-$2.02M) [Q2]

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3.50

233%

upside

Avg. target

$4.33

313%

upside

High target

$6

471%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 42 / 136 met price target	233%upside $3.50	Buy Reiterated	13 Aug 2024
Northland Capital Markets Carl Byrnes 50% 1-year accuracy 2 / 4 met price target	471%upside $6	Outperform Initiated	12 Aug 2024
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 42 / 136 met price target	233%upside $3.50	Buy Initiated	18 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about MDAI published over the past 30 days

Proactive Investors

Spectral AI preparing to seek FDA approval of DeepView burn assessment device

Spectral AI Inc (NASDAQ:MDAI) has outlined its US regulatory strategy for its DeepView AI burn system, a device designed to assess burn healing potential using multi-sepctral imaging and AI. The device, which received FDA Breakthrough Device Designation in 2018, provides rapid predictions on wound healing, assisting clinicians in treatment decisions.

Spectral AI preparing to seek FDA approval of DeepView burn assessment device

Spectral AI Outlines U.S. Regulatory Pathway for DeepView® System for Burn Indication

DALLAS, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided an outline of its regulatory pathway strategy to enter the U.S. market with its flagship DeepView® System for burn indication (“DeepView AI®-Burn”).

Spectral AI Outlines U.S. Regulatory Pathway for DeepView® System for Burn Indication

Proactive Investors

Spectral AI highlights potential of its wound analysis device to bridge burn care gaps

Spectral AI Inc (NASDAQ:MDAI) has highlighted how its DeepView System has been designed to broaden equity in burn care access and optimize healthcare resources following the release of a new report from the American Burn Association (ABA) which noted physical and economic barriers to burn care specialists. The report, published in the Journal of Burn Care & Research January/February 2024, spotlighted the uneven distribution of ABA-verified burn centers across the United States, particularly impacting rural and pediatric patients.

Spectral AI highlights potential of its wound analysis device to bridge burn care gaps

American Burn Association Study Highlights Inequities in Access to Specialized Burn Care

Spectral AI's DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare Resources Spectral AI's DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare Resources

American Burn Association Study Highlights Inequities in Access to Specialized Burn Care

Proactive Investors

Spectral AI secures government funding to advance battlefield wound assessment device

Spectral AI Inc (NASDAQ:MDAI) announced that it has been awarded more than $850,000 from the Medical Technology Enterprise Consortium (MTEC), a biomedical group collaborating with the US Army Medical Material Development Activity, to support the ongoing development of its DeepView SnapShot M. Spectral AI's DeepView SnapShot M is a handheld predictive wound healing device targeting battlefield applications based on its AI-driven DeepView System Platform, which uses multispectral imaging trained against a database of more than 340 billion clinically validated data points to assess a burn wound's healing potential before other medical intervention.

Spectral AI secures government funding to advance battlefield wound assessment device

Spectral AI Awarded Additional Funding from Medical Technology Enterprise Consortium to Support Ongoing Development of DeepView SnapShot M®

DALLAS, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received a new award of over $850,000 from the Medical Technology Enterprise Consortium (“MTEC”).

Spectral AI Awarded Additional Funding from Medical Technology Enterprise Consortium to Support Ongoing Development of DeepView SnapShot M®

Spectral AI to Participate in Upcoming Investor Conferences

DALLAS, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer, and Vince Capone, Chief Financial Officer, are scheduled to participate in the following investor conferences in New York City:

Spectral AI to Participate in Upcoming Investor Conferences

Proactive Investors

Spectral AI completes burn center enrollment early for pivotal study

Spectral AI Inc (NASDAQ:MDAI) announced that it has completed the enrollment of adult and pediatric patients at US burn centers for its pivotal study designed to validate the AI algorithm used by its DeepView system for the burn indication. The company said the data collected from these burn center patients will be used to pursue a De Novo classification from the US Food and Drug Administration (FDA) for the use of the DeepView System in burn centers.

Spectral AI completes burn center enrollment early for pivotal study

Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study

Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication

Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study

Proactive Investors

Spectral AI to present data from ongoing pivotal burn study at conference

Spectral AI Inc (NASDAQ:MDAI) announced that its chief medical consultant Dr Jeffrey Carter will present data from its ongoing multicenter study evaluating its DeepView System for burns at an upcoming conference. The DeepView System leverages non-invasive multispectral imaging technology and proprietary AI to detect non-healing areas of a wound following a burn injury.

Spectral AI to present data from ongoing pivotal burn study at conference

See News Rankings